Download PDF
TumorDiagnostik & Therapie 2016; 37(08): 446-450
DOI: 10.1055/s-0042-116420
Schwerpunkt: Melanome
Georg Thieme Verlag KG Stuttgart · New York

Übersicht – Systemtherapie des fortgeschrittenen metastasierten Melanoms

K. Buder-Bakhaya
,
J. C. Hassel
Further Information

Publication History

Publication Date:
24 October 2016 (online)

Also available at
    Permissions and Reprints

Melanome gehen aus den Melanozyten der Haut, selten auch der Schleimhäute, Uvea oder der Meningen hervor und gehören zu den aggressivsten Tumoren mit drastisch steigender Inzidenz und hoher Therapieresistenz [1]. Die Prognose der Erkrankung richtet sich im Wesentlichen nach der TNM-Klassifikation und dem daraus resultierenden Stadium des American Joint Committee on Cancer (AJCC) 2009, wobei die Chance für eine kurative Therapie in den frühen Tumorstadien am größten ist [2]. Durch neue Therapieansätze haben sich die Überlebensraten sowie die Anzahl der Patienten mit langfristiger Tumorkontrolle beim fernmetastasierten Melanom in den vergangenen Jahren erfreulicherweise deutlich erhöht.

 

  • Literatur

  • 1 Lo JA, Fisher DE. The melanoma revolution: from UV carcinogenesis to a new era in therapeutics. Science 2014; 346: 945-949
    CrossrefPubMedGoogle Scholar
  • 2 Balch CM, Gershenwald JE, Soong SJ et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199-6206
    CrossrefPubMedGoogle Scholar
  • 3 Eggermont AM, Kirkwood JM. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?. Eur J Cancer 2004; 40: 1825-1836
    CrossrefPubMedGoogle Scholar
  • 4 Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-954
    CrossrefPubMedGoogle Scholar
  • 5 Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-2516
    CrossrefPubMedGoogle Scholar
  • 6 Hauschild A, Grob JJ, Demidov LV et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012; 380: 358-365
    CrossrefPubMedGoogle Scholar
  • 7 Robert C, Karaszewska B, Schachter J et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 2015; 372: 30-39
    CrossrefPubMedGoogle Scholar
  • 8 Sosman JA, Kim KB, Schuchter L et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012; 366: 707-714
    CrossrefPubMedGoogle Scholar
  • 9 Long GV, Stroyakovskiy D, Gogas H et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 2015; 386: 444-451
    CrossrefPubMedGoogle Scholar
  • 10 Van Allen EM, Wagle N, Sucker A et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov 2014; 4: 94-109
    CrossrefPubMedGoogle Scholar
  • 11 Larkin J, Ascierto PA, Dreno B et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 2014; 371: 1867-1876
    CrossrefPubMedGoogle Scholar
  • 12 Dummer R, Schadendorf D, Ascierto P et al. Results of NEMO: A phase III trial of binimetinib (BINI) vs dacarbazine (DTIC) in NRAS-mutant cutaneous melanoma. J Clin Oncol 2016; 34
    PubMedGoogle Scholar
  • 13 Guo J, Si L, Kong Y et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol 2011; 29: 2904-2909
    CrossrefPubMedGoogle Scholar
  • 14 Hodi FS, Corless CL, Giobbie-Hurder A et al. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol 2013; 31: 3182-3190
    CrossrefPubMedGoogle Scholar
  • 15 Novartis NCT01028222: A Study of AMNN107 in the Treatment of Metastatic and / or Inoperable Melanoma Harboring a c-Kit Mutation (TEAM). Clinical trialsgov 2015
    PubMedGoogle Scholar
  • 16 Hodi FS, OʼDay SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723
    CrossrefPubMedGoogle Scholar
  • 17 Lebbe C, Weber JS, Maio M et al. Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies. Ann Oncol 2014; 25: 2277-2284
    CrossrefPubMedGoogle Scholar
  • 18 Dick J, Enk A, Hassel JC. Long-lasting responses under treatment with ipilimumab: an argument against maintenance therapy?. Dermatology 2015; 230: 8-10
    CrossrefPubMedGoogle Scholar
  • 19 Robert C, Long GV, Brady B et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372: 320-330
    CrossrefPubMedGoogle Scholar
  • 20 Topalian SL, Sznol M, McDermott DF et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014; 32: 1020-1030
    CrossrefPubMedGoogle Scholar
  • 21 Robert C, Schachter J, Long GV et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med 2015; 372: 2521-2532
    CrossrefPubMedGoogle Scholar
  • 22 Robert C, Ribas A, Wolchok JD et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014; 384: 1109-1117
    CrossrefPubMedGoogle Scholar
  • 23 Weber JS, DʼAngelo SP, Minor D et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015; 16: 375-384
    CrossrefPubMedGoogle Scholar
  • 24 Postow MA, Chesney J, Pavlick AC et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015; 372: 2006-2017
    CrossrefPubMedGoogle Scholar
  • 25 Larkin J, Chiarion-Sileni V, Gonzalez R et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 2015; 373: 23-34
    CrossrefPubMedGoogle Scholar
  • 26 Wolchok JD, Hoos A, OʼDay S et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009; 15: 7412-7420
    CrossrefPubMedGoogle Scholar
  • 27 Reule RB, North JP. Cutaneous and pulmonary sarcoidosis-like reaction associated with ipilimumab. J Am Acad Dermatol 2013; 69: e272-273
    CrossrefPubMedGoogle Scholar
  • 28 Hassel JC, Lee SB, Meiss F et al. Vemurafenib and ipilimumab: A promising combination? Results of a case series. Oncoimmunology 2016; 5: e1101207
    CrossrefPubMedGoogle Scholar
  • 29 Hu-Lieskovan S, Robert L, Homet Moreno B et al. Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges. J Clin Oncol 2014; 32: 2248-2254
    CrossrefPubMedGoogle Scholar
  • 30 Ribas A, Hodi FS, Callahan M et al. Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med 2013; 368: 1365-1366
    CrossrefPubMedGoogle Scholar
  • 31 Andtbacka RH, Ross M, Puzanov I et al. Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial. Ann Surg Oncol 2016; DOI: 10.1245/s10434-016-5286-0.
    PubMedGoogle Scholar
  • 32 Kranz LM, Diken M, Haas H et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature 2016; 534: 396-401
    CrossrefPubMedGoogle Scholar
  • 33 Rosenberg SA, Yang JC, Sherry RM et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011; 17: 4550-4557
    CrossrefPubMedGoogle Scholar
  • 34 Kocher M, Soffietti R, Abacioglu U et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22 952–26001 study. J Clin Oncol 2011; 29: 134-141
    CrossrefPubMedGoogle Scholar
  • 35 Margolin K, Ernstoff MS, Hamid O et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 2012; 13: 459-465
    CrossrefPubMedGoogle Scholar
  • 36 Rauschenberg R, Tabatabai G, Troost EG et al. [Melanoma brain metastases : Treatment options]. Hautarzt 2016; 67: 536-543
    CrossrefPubMedGoogle Scholar
  • 37 Ajithkumar T, Parkinson C, Fife K et al. Evolving treatment options for melanoma brain metastases. Lancet Oncol 2015; 16: e486-497
    CrossrefPubMedGoogle Scholar
  • 38 Hecht M, Zimmer L, Loquai C et al. Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients. Ann Oncol 2015; 26: 1238-1244
    CrossrefPubMedGoogle Scholar
  • 39 Lang N, Sterzing F, Enk AH et al. Cutis verticis gyrata-like skin toxicity during treatment of melanoma patients with the BRAF inhibitor vemurafenib after whole-brain radiotherapy is a consequence of the development of multiple follicular cysts and milia. Strahlenther Onkol 2014; 190: 1080-1081
    CrossrefPubMedGoogle Scholar